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Abstract: Breast cancer is the second greatest cause of cancer-related death in women. Resistance to 
endocrine treatments or chemotherapy is a limiting drawback. In this context, this work aims to 
evaluate the effects of cholesterol and mevalonate during tumor progression and their contribution 
in the onset of resistance to clinical treatments in use today. In this study, we demonstrated that 
cholesterol and mevalonate treatments were able to activate the estrogen-related receptor alpha 
(ERRα) pathway, increasing the expression levels of peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α), ERbB2/human epithelial receptor (HER2), tumor protein D52 
(TPD52), and NOTCH2 proteins in breast cancer cells. The activation of this pathway is shown to 
be responsible for intense metabolic switching, higher proliferation rates, sustained motility, the 
propagation of cancer stem-like cells (CSCs), and lipid droplet formation. All of these events are 
related to greater tumor propagation, aggressiveness, and drug resistance. Furthermore, the 
activation and expression of proteins induced by the treatment with cholesterol or mevalonate are 
consistent with those obtained from the MCF-7/TAMr cell line, which is largely used as a breast 
cancer model of acquired endocrine therapy resistance. Altogether, our data indicate that 
cholesterol and mevalonate are two metabolites implicated in breast cancer progression, 
aggressiveness, and drug resistance, through the activation of the ERRα pathway. Our findings 
enable us to identify the ERRα receptor as a poor prognostic marker in patients with breast 
carcinoma, suggesting the correlation between cholesterol/mevalonate and ERRα as a new possible 
target in breast cancer treatment. 




Breast cancer is a leading cause of cancer death in women, with almost half a million deaths 
worldwide per year [1], mainly because of tumor relapse and metastases [2,3]. Furthermore, cancer 
recurrence is associated with a resistance to common therapies and, for this reason, research aims to 
continuously identify new therapeutic targets, in order to overcome this phenomenon. In this context, 
several research studies have focused on lipid metabolism, storage, and mobilization [4,5]. In recent 
years, we have witnessed a reassessment of lipid droplets’ role, which are lipid-enriched organelles 
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mainly consisting of triacylglycerols and cholesterol esters, delimited by a phospholipidic monolayer. 
Both the content and nature of their different lipids are very varied, according to the cell type and 
physio-pathological conditions. Lipid droplets, initially considered inert cytoplasmic structures 
acting as a fat depot, assumed considerable interest due to their involvement in promoting cancer 
progression and anti-tumor resistance [5]. Recently, the mevalonate pathway, leading to the synthesis 
of sterols such as cholesterol and isoprenoids, has emerged as a promising therapeutic target [6,7]. In 
this pathway, 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) plays a key role; it catalyzes 
the production of mevalonate from 3-hydroxy-3-methylglutaryl-CoA and is considered the rate-
limiting enzyme for the pathway [8]. It is well-known that in many tumors, including those associated 
with breast cancer, a high expression of HMGCR is related to a higher tumor aggressiveness and poor 
prognosis [9,10], but it is not very clear which molecule of the pathway is responsible for these 
processes. Mevalonate is a pivotal intermediate for cholesterol synthesis, as well as a precursor of 
ubiquinone, which is a main character in mitochondrial bioenergetics [11,12]. It is well-accepted that 
the mevalonate pathway drives malignant transformation [7,13,14] and since statins are well-
established drugs used to lower serum cholesterol in patients, inhibiting the HMGCR [15], several 
studies have been performed to show that statins exert antitumor effects in human malignancies, 
including breast cancer [16,17]. However, the role of statins is debatable; indeed, other studies have 
failed to show any meaningful anti-tumor effect [18]. Preclinical and clinical studies of breast 
malignancies have demonstrated variable effects of statins, depending on the cell lines and cohorts, 
respectively [9,19]. Literature data has demonstrated that high serum cholesterol levels are risk 
factors in the onset of breast cancer and its metabolism is involved in the onset of resistance to therapy 
with tamoxifen in ER+ breast cancer [20,21]. Moreover, several reports have shown that cholesterol 
is closely related to the activation of estrogen-related receptor alpha (ERRα), which, for a long time, 
was considered to be an orphan nuclear receptor [22,23]. ERRα, along with the transcriptional 
coactivator peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-α), plays a 
key role in mitochondrial biogenesis [24–26], which is an important cancer feature. Based on this 
evidence, the goal of this study was to understand whether high levels of cholesterol, through ERRα 
pathway activation, are able to determine, by themselves, an aggressive and resistant tumor 
phenotype, or whether another biosynthetic intermediate is required to observe these phenomena. 
For this reason, in this study, we compared the effects of mevalonate and cholesterol treatment in 
promoting both proliferation and infiltrating capacity cells in the main breast cancer subtypes, as well 
as in inducing resistance to pharmacological treatments currently used in clinical practice. Our results 
show that cancer cells endured clear metabolic switching after mevalonate or cholesterol treatment, 
increasing in glycolytic and mitochondrial metabolism. They also demonstrate an increased 
propagation of cancer stem-like cells (CSCs), which are highly dependent on mitochondrial 
metabolism, as well as an enhancement in the formation of lipid droplets (LDs), which are key players 
in tumor recurrence, metastases, and drug resistance, respectively [27,28]. This evidence prompted 
us to speculate that cholesterol and its biosynthetic precursor, mevalonate, can drive aggressiveness 
and resistance to anti-cancer therapy used for breast cancer treatment, through the activation of ERRα 
and related pathways. 
2. Material and Methods 
2.1. Cell Cultures 
All breast cell lines used in this work (MCF7, T47D, MDA-MB-231, and MDA-MB-468) were 
purchased from the American Culture Collection (ATCC, Manassas, VA, USA). MCF7, T47D, and 
MDA-MB-231 cells were cultured in DMEM/F12 (Sigma Aldrich, St. Louis, MO, USA) supplemented 
with 10% Fetal Bovine Serum (FBS, Sigma Aldrich), 2 mM l-glutamine (Gibco, Life Technologies, 
Waltham, MA, USA), and 1% penicillin/streptomycin (Gibco, Life Technologies). DMEM (High 
Glucose) (Sigma Aldrich) supplemented with 10% FBS, 2 mM l-glutamine, and 1% 
penicillin/streptomycin was used to culture MDA-MB-468 cells. Treatments were performed in the 
above-mentioned media. The concentrations of mevalonate and cholesterol used in this study were 
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chosen based on the results obtained from previous studies [27,29]. All cell lines were cultured at 37 
°C in 5% CO2 in a humidified atmosphere, as previously described [30,31]. 
2.2. Immunoblot Analysis 
For immunoblot analysis, cells were grown to 70–80% confluence and treated with 10 µM 
cholesterol, 1 mM mevalolactone (subsequently defined as mevalonate for simplicity), or EtOH, or 
co-treated with 5 µM XCT790 for 48 h. Then, cells were harvested and lysed in 200 µL of lysis buffer 
to produce the total cell lysates, as previously described [32,33]. The same amounts of proteins from 
total lysates were resolved on SDS-polyacrylamide gel, transferred to a nitrocellulose membrane, and 
probed with appropriate primary antibodies (Santa Cruz, Biotechnology, Dallas, TX, USA; Abcam, 
Cambridge, UK). Incubation with the anti-β-actin antibody (Santa Cruz, Biotechnology, Dallas, TX, 
USA) was used to confirm equal loading and transfer. The complex formed between the antigen and 
antibody was detected by incubation of the membranes with peroxidase-coupled goat anti-mouse or 
goat anti-rabbit antibodies and was revealed using the ECL System (Bio-Rad Laboratories, Hercules, 
CA, USA), as previously described [34]. Then, the bands of interest were quantified by using ImageJ 
software (Image J, Bethesda, MD, USA). 
2.3. Cell Cycle Analysis 
Cell cycle analysis was performed as previously reported [35]. MCF7, T47D, MDA-MB-231, and 
MDA-MB-468 cells, seeded in 6-well plates at a density of 1 × 105 cells/well, were treated with EtOH, 
10 µM cholesterol, or 1 mM mevalonate for 5 days. After treatment, cells were detached from the 
wells using trypsin, washed twice with chilled PBS, and centrifuged at 1500 rpm for 5 min. Cells were 
fixed by re-suspending the pellets in 70% ethanol for 30 min at 4 °C. Then, cells were washed twice 
with PBS and stained in 3.8 mM sodium citrate, 50 µg/mL propidium iodide [36], 100 µg/mL RNAse, 
and 0.1% Igepal in PBS for 1 h at 37 °C. Next, samples were subjected to cytofluorimetric analysis 
using ATTUNETM (Life Technologies, Grand Island, NY, USA). 
2.4. Wound-Healing Assay 
The wound-healing assay was performed as previously reported [32,37]. Cells were grown to 
confluence and the monolayers were then scraped using a p200 tip and treated with EtOH, 10 µM 
cholesterol, or 1 mM mevalonate. Wound closure was monitored for 24 h and cells were then 
subjected to phase-contrast light microscopy. Pictures were taken at 10× magnification using the 
EVOS FL Auto 2 microscope (Life Technologies, Grand Island, NY, USA). The rate of wound healing 
was quantified from the picture using ImageJ software and standard deviations were determined by 
using GraphPad-Prism 8.3.0 software (GraphPad Inc., San Diego, CA, USA). 
2.5. Seahorse XFe96 Metabolic Profile Analysis 
Extracellular acidification rates (ECAR) and real-time oxygen consumption rates (OCR) for cells 
treated with mevalonate or cholesterol were assessed using the Seahorse Extracellular Flux (XFe96) 
analyzer (Seahorse Bioscience, Billerica, MA, USA), in order to evaluate the glycolytic and 
mitochondrial function, respectively. The analysis was performed as previously described [38]. 
Briefly, 1 × 104 cells/well were seeded into XFe96-well cell culture plates and incubated overnight in 
complete medium. Then, cells were treated with mevalonate or cholesterol (1 mM and 10 µM) or co-
treated with 5 µM XCT790 for 48 h. Next, cells were washed in pre-warmed XF assay media (or for 
OCR measurement, XF assay media supplemented with 10 mM glucose, 1 mM Pyruvate, and 2 mM 
l-glutamine, and adjusted at pH 7.4). Cells were then maintained at 37 °C in a non-CO2 incubator for 
1 h in 175 µL/well of XF assay media. During the incubation time, we filled up the injection ports in 
the XFe96 sensor cartridge with 25 µL of 80 mM glucose, 9 µM oligomycin, and 1 M 2-deoxyglucose 
(for ECAR measurement), or 10 µM oligomycin, 9 µM FCCP, 10 µM rotenone, and 10 µM antimycin 
A (for OCR measurement), dissolved in the XF assay media. Measurements were normalized by the 
protein content (SRB assay). Data were analyzed using GraphPad through one-way ANOVA and 
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Student’s t-test calculations and XFe96 software. All experiments were performed in quintuplicate, 
three times, independently. 
2.6. Mitochondrial Membrane Potential and Mass Analysis 
To measure the mitochondrial membrane potential and mass, cells were stained with the CM-
H2TMRos or MitoTracker Deep Red FM probes, respectively (ThermoFisher), as previously 
described [39]. The accumulation of the CM-H2TMRos probe in mitochondria is dependent upon the 
membrane potential, while the MitoTracker Deep Red FM is used to label mitochondria, according 
to the manufacturer’s protocols. Briefly, 1 × 105 cells/well were seeded in 6-well plates and treated 
with mevalonate, cholesterol, or EtOH for 5 days. After treatment, cells were harvested, rinsed, and 
incubated in 10 nM MitoTracker Orange solution or 10 nM MitoTracker Deep Red FM in PBS for 30 
min at 37 °C. After staining, cells were fixed with 3.7% formaldehyde in PBS at 37 °C for 15 min, 
rinsed, and resuspended in PBS. Samples were then subjected to cytofluorimetric analysis by using 
the SONY SH800 Cell Sorter (Sony Corporation, Minato, Tokyo, Japan). 
2.7. Mammosphere Formation Assay 
A single cell suspension was prepared using enzymatic (1× Trypsin-EDTA, Sigma Aldrich) and 
manual disaggregation (25-gauge needle). Cells were plated at a density of 5000 cells/well in a 
mammosphere medium (DMEM-F12 w/o red phenol + B27 supplement + 20 ng/mL EGF + 
penicillin/streptomycin) under non-adherent conditions in 6-well plates pre-coated with 2-
hydroxyethylmethacrylate (poly-HEMA, Sigma Aldrich), as previously described [40]. Then, cells 
were treated with mevalonate or cholesterol at concentrations of 1 mM or 10 µM, respectively. Vehicle 
alone (EtOH)-treated cells were processed in parallel as a control. Cells were grown for five days and 
maintained in a humidified incubator at 37 °C. After five days of culture, 3D-spheres > 50 μm were 
counted using an eye piece (“graticule”), and the percentage of cells plated that formed spheres was 
calculated, being referred to as the percent mammosphere formation efficiency (MFE). 
2.8. Immunofluorescence Assay 
Breast cancer cells were seeded on coverslips in 6-well plates at a density of 1 × 105 cells/well, 
and cultured overnight in complete medium. Next, cells were treated for 48 h with mevalonate, 
cholesterol (1 mM or 10 µM, respectively), or EtOH. After treatment had ended, cells were fixed with 
ice cold methanol for 20 min at −20 °C, washed three times for 5 min with Tris buffered saline (TBS, 
Sigma-Aldrich), and incubated for blocking with 10% donkey serum (Sigma-Aldrich) in TBS for 40 
min at 37 °C. Then, cells were incubated for 40 min at 37 °C in anti-PLIN monoclonal antibody 
(Abcam), diluted to 1:200, as previously described [34]. Next, they were washed three times for 5 min 
with TBS to discard excess primary antibody, incubated for 40 min at 37 °C in anti-rabbit IgG-FITC 
(Alexa Fluor 488) diluted to 1:500, and subsequently washed three times for 5 min with TBS. DAPI 
(Sigma-Aldrich, Milan, MI, IT) was also used to stain nuclei. Pictures were taken at 20× magnification 
using the Olympus BX41 microscope with CSV1.14 software, using a CAMXC-30 for image 
acquisition. 
2.9. Sulforhodamine B (SRB) Assay 
To assess the cell viability, we used the sulforhodamine B (SRB) assay, as previously described 
[41]. Briefly, 2 × 105 cells/well were seeded in 48-well plates and cultured overnight to allow the cells 
to attach. Then, cells were treated with mevalonate or cholesterol in the presence or absence of 4-OH 
tamoxifen or doxorubicin, for 48 h. At the end of the treatment, cell monolayers were fixed with 
chilled 10% (wt/vol) trichloroacetic acid for 15 min at 4 °C. Plates were then washed with PBS and 
allowed to dry. Next, cells were stained with 0.04% (wt/vol) SRB for 30 min, after which the excess 
dye was removed by washing repeatedly with 1% (vol/vol) acetic acid. The protein-bound dye was 
dissolved in 10 mM Tris base solution for OD determination at 510 nm using a VarioskanTM LUX 
microplate reader (ThermoFisher). 
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2.10. Kaplan–Mayer Analysis 
The prognostic value of ERRα in breast cancer was evaluated by performing a Kaplan–Meier 
(K–M) analysis using the updated version of a publicly available microarray database from breast 
cancer patients (http://kmplot.com/analysis/index.php?p=service&cancer=breast). Relapse-free 
survival (RFS) was evaluated in a cohort of patients with any breast cancer subtype. Kaplan–Meier 
correlations were plotted for high (above median, in red) and low (below median, in black) gene 
expression. Biased array data were excluded from the analysis. Hazard-ratios were calculated, at the 
best auto-selected cut-off, and p-values were calculated using the log-rank test and plotted in R. K–
M curves were also generated online using the K–M plotter (as high-resolution TIFF files), as 
previously reported [42]. 
2.11. Statistical Analysis 
Data are presented as mean values ± standard deviation, obtained from ≥3 independent 
experiments, with ≥3 replicates per experiment, unless otherwise stated. Statistical significance was 
measured by using the analysis of variance (ANOVA) test. A p-value ≤ 0.05 was considered 
statistically significant. Non-linear regression analysis (GraphPad Prism 8.3.0) was used to generate 
sigmoidal dose-response curves to calculate the IC50 values [43]. 
3. Results 
3.1. Mevalonate and Cholesterol Activate the ERRα Pathway, Increasing the Levels of Related Proteins 
In order to evaluate the role of cholesterol and its biosynthetic precursor mevalonate in breast 
cancer progression, and since the goal of our work was to evaluate whether high cholesterol levels 
were responsible for greater tumor aggressiveness and resistance phenomena, we supplemented 
already cholesterol-containing media (10% FBS medium) with the indicated amounts of cholesterol 
and mevalonate, focusing our attention on the ability of the two metabolites to activate the ERRα 
pathway in four different breast cancer cell lines. We used cell lines characterized by important 
differences in the three main receptors conventionally used for breast cancer subtyping: The estrogen 
receptor (ER), progesterone receptor (PR), and human epithelial receptor (HER 2). In particular, we 
employed MCF-7 and T47D, which are two breast cancer cell lines characterized by the presence of 
ERα, and MDA-MB-231 and MDA-MB-468, which are two breast cancer cell lines characterized as 
triple negative. We found that, in all breast cancer cell lines examined, cholesterol and mevalonate 
treatment induced a significant increase in ERRα expression levels, as well as in the levels of the 
related protein PGC-1α—the coactivator needed for the activation of the ERRα pathway—by 
promoting mitochondrial biogenesis [44] (Figure 1). 
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Figure 1. Mevalonate and cholesterol treatment increases the expression levels of estrogen-related 
receptor alpha (ERRα) pathway-related proteins. Immunoblot analysis of main proteins involved in 
the ERRα pathway and cell aggressiveness after treatment with 1 mM mevalonate or 10 µM 
cholesterol for 2 days. Optical density of their expression levels by densitometry obtained in MCF-7 
(a), T47D (b), MDA-MB-231 (c), and MDAMB-468 (d). Values represent the mean ± SD of three 
independent experiments. * p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001; **** p-value < 0.0001. 
Additionally, the treatment resulted in an increase of the expression levels of ERbB2/HER2, 
which is a protein associated with the ERRα pathway with considerable functions in the maintenance 
of cancer progression, such as the sustenance of proliferation, and significant functions in the 
metabolism of tumor cells [45,46] (Figure 1). Treatment was also related to increasing levels of 
NOTCH2, which is a relevant protein in breast cancer propagation and associated with a poor 
prognosis, indicating the important ability of cholesterol and mevalonate to support the propagation 
and stemness of breast cancer cells (Figure 1) [47]. The ERRα activation was also evaluated under 
starvation conditions, and a similar trend was demonstrated (Figure S1). Furthermore, as shown in 
Figure 2, we compared the expression levels of the above-mentioned proteins in treated MCF-7 cells 
to those detected in the MCF-7/TAMr cell line, which differs from normal MCF-7 cells by having an 
acquired resistance to tamoxifen. MCF-7 cells treated with mevalonate or cholesterol exhibited 
expression levels of both ERRα and related proteins comparable to those of MCF-7/TAMr cells. 
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Figure 2. In MCF-7, mevalonate and cholesterol treatment induces similar expression levels of ERRα 
pathway-related proteins to MCF-7/TAMr cells. Immunoblot analysis of the main proteins involved 
in the ERRα pathway and cell aggressiveness after treatment with 1 mM mevalonate or 10 µM 
cholesterol for 2 days. The western blot shown in Figure 2 is the same as the one shown in Figure 1 
for MCF7 cells. The optical density of their expression levels was acquired by densitometry obtained 
in MCF-7 versus MCF-7/TAMr. Values represent the mean ± SD of three independent experiments. * 
p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001; **** p-value < 0.0001. 
In order to confirm the ability of cholesterol or mevalonate to induce the activation of the ERRα 
pathway in breast cancer cells, we monitored the ERRα expression levels in cholesterol/mevalonate-
treated cells in the presence of XCT790, which is a well-known selective ERRα inhibitor. The presence 
of the inhibitor in treated MCF-7 cells (representative of ERα cells), as well as in treated MDA-MB-
231 (representative of triple negative cells), revealed decreased expression levels of both ERRα and 
ERbB2 (Figure 3 and Figure S2). 
 
Figure 3. Co-treatment of XCT790 and mevalonate or cholesterol reduces the expression levels of both 
ERRα and the main correlated proteins in MCF-7 cells. Immunoblot analysis of ERRα and 
ERbB2/human epithelial receptor (HER2) after co-treatment with 5 µM XCT790, 1 mM mevalonate, 
or 10 µM cholesterol, for 2 days. Results obtained from densitometry were related to their own 
control. Values represent the mean ± SD of three independent experiments. ** p-value < 0.01; *** p-
value < 0.001; ns: not significant. 
These results, together with the comparable expression levels obtained in treated MCF-7 cells 
with respect to the MCF-7/TAMr cells, suggest that the ERRα pathway has a role in the acquisition 
of resistance. 
3.2. Cholesterol and Its Biosynthetic Precursor, Mevalonate, Lead Cell Cycle Progression 
Based on the different pathways activated in breast cancer cells by cholesterol or mevalonate 
and given the pivotal role that they play in promoting tumor proliferation (in particular, 
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ERbB2/HER2 and NOTCH2 signaling), we evaluated the effects of cholesterol or mevalonate 
treatment on cell cycle progression. The results showed that five days of mevalonate or cholesterol 
treatment induced a noticeable increase in the G2/M phase (Figure 4), suggesting a greater 
proliferation rate in all breast cancer cells examined. The proliferative effects were confirmed by cell 
growth analysis, performed by the SRB assay (Figure S3). 
 
Figure 4. Mevalonate and cholesterol promote cell cycle progression. Cytofluorimetric analysis of 
MCF7, T47D, MDA-MB-231, and MDA-MB-468 cells treated for 5 days with EtOH (control), 1 mM 
mevalonate, or 10 µM cholesterol and stained with PI; graphs represent the percentage of the total 
events in the samples (highlighting the increase in the G2/M phase). Values represent the mean ± SD 
of three independent experiments. * p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001; **** p-value < 
0.0001. 
3.3. Mevalonate and Cholesterol Improve the Motility of Breast Cancer Cell Lines 
Next, cell motility, which is a hallmark of cancer aggressiveness [48], was evaluated in all four 
breast cancer cell lines. For this purpose, cells were seeded, left to reach confluence, and subjected to 
the wound-healing scratch assay; then, they were treated with mevalonate or cholesterol for 24 h. The 
pictures were taken using phase-contrast microscopy. Figure 5 and figures S4–S7 show that, after 
treatment, cells were able to close the wound faster than each control, highlighting the effects of 
cholesterol and mevalonate in enhancing cell motility. 
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Figure 5. Mevalonate and cholesterol increase breast cancer cell motility. Wound-healing scratch 
assay in MCF7, T47D, MDA-MB-231, and MDA-MB-468 cells treated for 24 h with EtOH (control), 1 
mM mevalonate, or 10 µM cholesterol. Wound closure in MCF-7 (a), T47D (b), MDA-MB-231 (c), and 
MDAMB-468 (d). Values are expressed as the mean ± SD of three independent experiments. * p-value 
< 0.05; ** p-value < 0.01. 
3.4. Increase of Mitochondrial Activity and Energetic Metabolism in Mevalonate- and Cholesterol-Treated 
Breast Cancer Cells 
Based on the immunoblot results in which we demonstrated high expression levels of ERRα and 
of PGC1α, as well as high expression levels of ERbB2/HER2, representing a tyrosine kinase receptor 
highly implicated in the control of various metabolic processes, we analyzed the metabolic profile of 
all breast cancer cell lines after treatment with mevalonate or cholesterol for 48 h, by using a Seahorse 
XFe96 analyzer. The mitochondrial function was assessed by performing a Mito Stress test. 
Monitoring the oxygen consumption rate (OCR) after sequential injections of oligomycin, FCCP, and 
an antimycin/rotenone mix allowed us to evaluate the mitochondrial function parameters, such as 
basal respiration and maximal respiration. Mevalonate and cholesterol treatment induced a marked 
increase of all the above-mentioned mitochondrial respiration parameters (Figure 6). Additionally, 
we found increased ATP production, which was assessed using a CellTiter-glo assay. Glycolytic 
function was detected by monitoring the extracellular acidification rate (ECAR); sequential injections 
of glucose, oligomycin, and 2-deoxy-D-glucose (2-DG) allowed us to evaluate the glycolytic function 
parameters, such as the glycolytic capacity and glycolytic reserve. Interestingly, MCF-7, T47D, and 
MDA-MB-231 cells, treated with mevalonate or cholesterol for 48 h, showed an increase in glycolysis 
and in all glycolytic function parameters (Figure 7), while the ECAR profile and other glycolytic 
function parameters were not affected in MDA-MB-468 cells, which may have been due to the higher 
basal glycolytic activity (Figure 6). 
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Figure 6. Mevalonate and cholesterol increase metabolic functions in breast cancer cells. A Seahorse 
XFe96 analyzer was employed to analyze both mitochondrial respiration and the glycolytic function 
in MCF-7, T47D, MDA-MB-231, and MDA-MB-468 cells treated with mevalonate or cholesterol for 48 
h, by monitoring the oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR), 
respectively, as indicated. OCR representative tracings of breast cancer cells treated with EtOH 
(control), 1 mM mevalonate, or 10 µM cholesterol and histograms of mitochondrial respiration 
parameters. ECAR representative tracings of breast cancer cells treated with EtOH (control), 1mM 
mevalonate, or 10 µM cholesterol and histograms of glycolytic function parameters. Values are 
expressed as the mean ± SEM of five biological replicates of three independent experiments. * p-value 
< 0.05; ** p-value < 0.01; *** p-value < 0.001; **** p-value < 0.0001. 
To confirm the OCR results, the mitochondrial mass, mitochondrial potential, and their ratio, 
which is an index of the mitochondrial function, were evaluated after 5 days of treatment with 
cholesterol or mevalonate in all examined breast cancer lines. 
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Figure 7. Mevalonate and cholesterol induce mitochondrial activity. Mitochondrial mass (a) and 
potential (b) after 5 days of 1 mM mevalonate or 10 µM cholesterol treatment were assessed using 
MitoTracker Deep Red FM and MitoTracker Orange CM-H2TMRos probes, respectively, in MCF7, 
T47D, MDA-MB-231, and MDA-MB-468. (c) Ratio between potential and mitochondrial mass. Values 
are expressed as the mean ± SD of three independent experiments. * p-value < 0.05; ** p-value < 0.01; 
*** p-value < 0.001. 
We observed an increased mitochondrial mass in all studied triple negative breast cancer cell 
lines; conversely, no change was found in ERα+ cell lines (Figure 7). However, in all cell lines, both 
the mitochondrial potential and the ratio of mitochondrial membrane potential versus mitochondrial 
mass increased (Figure 7), confirming the OCR results obtained by Seahorse analysis. Overall, our 
results highlight the ability of cholesterol and mevalonate to increase the energy metabolism of breast 
cancer cells, upregulating glycolysis and oxidative phosphorylation, which are the two main 
pathways of cell metabolism. Moreover, the metabolic functions of MCF-7/TAMr and MCF-7 cells 
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treated with mevalonate or cholesterol were compared (Figure 8), highlighting the ability of the two 
metabolites to induce, in MCF-7, the same metabolic profile of ERα+ cells insensible to endocrine 
therapy. 
 
Figure 8. Mevalonate and cholesterol increase the metabolic functions in MCF-7, inducing the same 
metabolic profile of MCF-7/TAMr. A Seahorse XFe96 analyzer was employed to analyze the 
mitochondrial respiration and glycolytic function in MCF-7 cells treated with mevalonate or 
cholesterol for 48 h (the seahorse analysis in Figure 8 is the same as the one shown in Figure 6 for 
MCF7 cells) by monitoring the oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR), respectively, compared with MCF-7/TAMr. Histograms of mitochondrial respiration 
parameters and histograms of glycolytic function parameters are also shown and compared with 
untreated MCF-7/TAMr. Values are expressed as the mean ± SEM of five biological replicates of three 
independent experiments. * p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001; **** p-value < 0.0001. 
In addition, we found that both the mitochondrial potential and the ratio of mitochondrial 
membrane potential versus mitochondrial mass of MCF-7 cells were also comparable to those of 
MCF-7/TAMr (Figure 9). 
 
Figure 9. MCF-7 cells treated with mevalonate or cholesterol showed mitochondrial activity 
comparable to that of the MCF-7/TAMr cell line. Mitochondrial mass (a) and potential (b) after 5 days 
of 1 mM mevalonate or 10 µM cholesterol treatment were assessed using MitoTracker Deep Red FM 
and MitoTracker Orange CM-H2TMRos probes, respectively, in MCF7 (mitochondrial mass and 
mitochondrial potential analysis shown in Figure 8 is the same as the one shown in Figure 7 for MCF7 
cells) versus MCF-7/TAMr. (c) Ratio between potential and mitochondrial mass. Values are expressed 
as the mean ± SD of three independent experiments. * p-value < 0.05; *** p-value < 0.001; **** p-value 
< 0.0001. 
The strong energy boost detected in all examined cell lines in response to treatment with 
cholesterol or mevalonate, its metabolic precursor, prompted us to hypothesize that it could be due 
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to ERRα pathway activation and increased expression levels of ERbB2/HER2, which are proteins 
involved in metabolism regulation and modulated by ERRα. The implication of the ERRα pathway 
in the observed metabolic effects was confirmed by seahorse analysis performed in MCF-7 co-treated 
with cholesterol or mevalonate and XCT790, which is a selective inverse agonist ligand of ERRα 
(Figure 10). In these conditions, no metabolic boost induced by the two metabolites was observed. 
 
Figure 10. MCF-7 cells co-treated with mevalonate or cholesterol and XCT790 showed no relevant 
metabolic effects on the MCF-7 cell line. A Seahorse XFe96 analyzer was employed to analyze the 
mitochondrial respiration and glycolytic function in MCF-7cells treated with the vehicle alone or co-
treated with 5 µM XCT790 and mevalonate or cholesterol (1 mM and 10 µM, respectively) for 48 h by 
monitoring the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), 
respectively. Histograms of mitochondrial respiration parameters and histograms of glycolytic 
function parameters are also shown. Values represent the mean ± SEM of five biological replicates of 
three independent experiments. * p-value < 0.05; ** p-value < 0.01. 
3.5. Mevalonate and Cholesterol Increase Breast Cancer Stem Cell Propagation 
Since cholesterol and its biosynthetic precursor, mevalonate, were revealed to strongly increase 
the cancer cell mitochondrial function, next, we investigated whether they may affect cancer stem cell 
propagation. CSCs are a sub-population of tumor cells responsible for therapy resistance and tumor 
recurrence [49], and mitochondrial function is required for their anchorage-independent survival and 
propagation [30]. To this end, we monitored the mammosphere formation efficiency (MFE) after 
treatment for 5 days with mevalonate and cholesterol. We found that mevalonate and cholesterol 
treatment significantly increased breast cancer stem cell propagation (Figure 11), suggesting that the 
activation of ERRα and related pathways, by cholesterol and mevalonate, may work together to 
determine an aggressive and likely resistant breast cancer phenotype. 
Cells 2020, 9, 1819 14 of 24 
 
 
Figure 11. Cholesterol and mevalonate promote cancer stem-like cell (CSC) propagation. A 
mammosphere formation efficiency assay was performed on breast cancer cells MCF7, T47D, MDA-
MB-231, and MDA-MB-468 after treatment for 5 days with 1 mM mevalonate or 10 µM cholesterol. 
Mammospheres were grown in no-attachment conditions and counted using an Olympus BX41 (4× 
magnification) microscope. 3D-spheres > 50 μm were counted using an eye piece (“graticule”), and 
the percentage of cells plated that formed spheres was calculated and referred to as the percent 
mammosphere formation efficiency (MFE). Results are expressed as the mean ± SD of three 
independent experiments. Scale bars are 125 µm. **** p-value < 0.0001. 
3.6. Increase of Lipid Droplet Formation in Mevalonate- and Cholesterol-Treated Breast Cancer Cells 
We then evaluated lipid droplet (LDs) formation, which is an additional hallmark that could 
play an important role in contributing to the aggressive phenotype and resistance onset. Lipid 
droplets are storage organelles present in low numbers in most cell types, while increased numbers 
can occur in cancer cells. In recent years, much focus has been given to the lipid droplets and in 
particular, to the relationship between lipid droplets and resistance to chemotherapy drugs by tumor 
cells [50]. Based on the involvement of LDs in aggressive cancer phenotypes, we evaluated perilipin-
2, which is a protein constituent of LDs, after treatment with mevalonate or cholesterol, by 
immunofluorescence and immunoblot analyses. The results (Figure 12) showed a marked increase in 
perilipin-2 expression levels in treated cells. Interestingly, the immunofluorescence study revealed 
differences in the perilipin-2 content, which increased in parallel with the aggressiveness of the 
analyzed breast cancer cells. Moreover, mevalonate and cholesterol treatment resulted in higher 
expression levels of a protein closely connected to ERbB2 and LD formation,—tumor protein D52 
(TPD52)—representing an oncogene whose overexpression has been associated with poor outcomes 
in breast malignancies [51]. Furthermore, the higher perilipin-2 and TPD52 expression levels induced 
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by cholesterol or mevalonate treatment were dependent on ERRα activity, since XCT790 treatment 
abolished them (Figure 12 and Figure S2). 
 
Figure 12. Cholesterol and mevalonate promote perilipin-2 expression through ERRα activation. (a) 
Immunofluorescence and (b) immunoblot analysis of perilipin-2 and TPD52 were performed on 
breast cancer cells MCF7, T47D, MDA-MB-231, and MDA-MB-468 after treatment for 48 h with 1 mM 
mevalonate or 10 µM cholesterol. (c) Immunoblot analysis on MCF-7 of perilipin-2 and TPD52 after 
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co-treatment with 5 µM XCT790, 1 mM mevalonate, or 10 µM cholesterol for 2 days. Pictures were 
taken at 20× magnification. Scale bars are 25 µm. Results are expressed as the mean ± SD of three 
independent experiments. * p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001; **** p-value < 0.0001. 
Finally, we compared perilipin-2 and TPD52 expression levels in MCF-7/TAMr versus MCF-7 
cells treated with mevalonate or cholesterol (Figure 13) and obtained comparable results. 
 
Figure 13. In MCF-7 cells, mevalonate and cholesterol treatment induces perilipin expression levels 
comparable to those of MCF-7/TAMr cells. (a) Immunofluorescence of perilipin-2 and (b) immunoblot 
analysis of perilipin-2 and TPD52 after treatment with 1 mM mevalonate or 10 µM cholesterol for 2 
days. The immunofluorescence shown in (a) and the western blot shown in (b) are the same as the 
those shown in Figure 12 for MCF-7 cells. Pictures were taken at 20× magnification. Scale bars are 25 
µm. Results are expressed as the mean ± SD of three independent experiments. * p-value < 0.05; ** p-
value < 0.01; **** p-value < 0.0001. 
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3.7. Mevalonate and Cholesterol Induce Chemotherapy Drug Resistance 
Since we established that cholesterol and mevalonate, through ERRα, activate pathways 
involved in tumor progression and drug resistance, we asked whether the two metabolites were 
really able to confer resistance to drugs currently used in clinical practice, such as tamoxifen and 
doxorubicin. To this end, using an SRB assay, we evaluated the cell viability after 48 h of treatment 
with mevalonate or cholesterol in the presence or absence of 4-OH-tamoxifen or doxorubicin. We 
compared the results of each breast cancer cell line versus each untreated control. As shown in Figure 
14, all of the examined breast cancer cell lines exhibited an increase in the resistance to the 4-OH-
tamoxifen or doxorubicin, confirming that cholesterol and mevalonate induce chemotherapy 
resistance in breast cancer cells. The observed doxorubicin resistance finds validation in a previous 
report, which linked the antitumor effect of doxorubicin to its inhibitory effect on the HMGCR 
function [52]. Moreover, to confirm the close correlation between drug resistance induced by 
cholesterol and mevalonate through both ERRα and related pathway activation, we performed the 
same experiment in the presence of XCT790. We used the MCF-7 cell line (representative of ER+ cells) 
(Figure 14) and MDA-MB-231 cell line (representative of triple negative cells) (Figure S2). The results 
evidenced that XCT790 is able to revert the cholesterol and mevalonate effect to induce tamoxifen 
and doxorubicin resistance, confirming that the resistance induction is mediated by ERRα and related 
pathway activation. 
 
Figure 14. Cholesterol and mevalonate promote resistance to common chemotherapy drugs through 
ERRα activation. Breast cancer cells (a) MCF7 and T47D and (b) MDA-MB-231 and MDA-MB-468 
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were treated with 1 mM mevalonate or 10 µM cholesterol in the presence of 5 µM 4-OH-tamoxifen 
(4-OHT) or 1 µM doxorubicin (Dox) for 48 h. (c) MCF-7 cells were treated with 1 mM mevalonate or 
10 µM cholesterol in the presence of 4-OH-tamoxifen (4-OHT) or doxorubicin (Dox) and 5 µM XCT790 
for 48 h. Cell viability was assessed using SRB. The results obtained from the SRB assay were related 
to their own control. Values are indicated as the mean ± SD of three independent experiments. * p-
value < 0.05; ** p-value < 0.01; *** p-value < 0.001; **** p-value < 0.0001. 
3.8. High Levels of ERRα are Associated with a Poor Prognosis in Breast Cancer Patients 
Based on the results above, in which we demonstrated that the activation of ERRα by cholesterol 
or mevalonate was able to confer resistance to chemotherapy, as well as to promote breast cancer 
aggressiveness, we assessed the prognostic value of ERRα in patients with breast cancer (all breast 
cancer subtypes). We used publicly available transcriptional profiling data from tumors of breast 
cancer patients (Gene Probe 203193_at). The hazard-ratio for ERRα was 0.87 (N = 3571 patients) 
(Figure 15 and Table 1) for relapse-free survival (RFS), highlighting that the expression of ERRα is a 
negative prognostic marker in patients with breast cancer. 
 
Figure 15. Prognostic value of ERRα in human breast cancer subtypes. To assess the clinical relevance 
of ERRα, we determined the ERRα mRNA transcript levels in human breast cancer patient cohorts 
with long-term follow-up data. Note that high mRNA levels of ERRα show an association with 
reduced relapse-free survival (RFS), i.e., a higher tumor recurrence. 
Table 1. Prognostic value of ERRα in human breast cancer subtypes: Tumor recurrences (RFS). 
Symbol Gene Probe HR (Hazard Ratio) p-Value (Log Rank Test) 
All Breast Cancer Subtypes n = 3571 
ERRα/ESRRA 203193_at 0.87 0.023 
4. Discussion 
Recurrence, metastasis, and therapy resistance remain unmet clinical needs that require new 
therapeutic strategies [53]. In this study, we focused our attention on cholesterol and its biosynthetic 
precursor, mevalonate, as two biomolecules that can play key roles during the progression of breast 
cancer and resistance to common therapy. It is well-known that the cholesterol level is a risk factor 
of breast cancer [54], promotes resistance to tamoxifen in ER+ breast cancer cells, and is also 
associated with ERRα pathway activation. Considering this, we analyzed the metabolic and 
biological changes that cholesterol and mevalonate are able to induce in breast cancer cells. We used 
a panel of breast cancer cells that reflect the biological diversity of the different breast cancer 
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subtypes, such as MCF-7, T47D, MDA-MB-231, and MDA-MB-468 cells. Our results showed that 
mevalonate and cholesterol are able to activate the ERRα pathway, regardless of the subtype, 
promoting the expression of two main proteins: PGC-1α, an important co-activator of ERRα 
signaling, acting on mitochondrial biogenesis [55] and ERbB2/HER2, which is a tyrosine kinase 
receptor closely dependent on the ERRα pathway and implicated in cancer maintenance and 
progression [45,46]. These two pathway are strictly related as they drive the metabolism of breast 
cancer cells. Moreover, we found that cholesterol or mevalonate treatment induces a higher 
expression of TPD52, which is the tumor protein D52 dependent on ERbB2/HER2 [56]. Surprisingly, 
the expression level of these proteins in MCF-7 cells treated with cholesterol or mevalonate was 
comparable to that observed in MCF-7/TAMr cells resistant to tamoxifen, confirming that cholesterol 
or mevalonate, acting on the ERRα pathway, may induce aggressive and resistant phenotypes. The 
activation of the ERRα pathway by the treatment was also confirmed by using XCT790, which is a 
selective ERRα inhibitor. In order to study the behavior of cholesterol or mevalonate during cancer 
progression, we focused the attention on the main cancer features, such as cell proliferation and 
migration. Abnormal cellular proliferation due to a dysregulated cell cycle is one of the hallmarks of 
cancer [57]. Using cytofluorimetric analysis, we demonstrated that mevalonate and cholesterol 
promote cell cycle progression, increasing the G2/M phase, with the latter being an immediate 
consequence of the previously observed pathway activation. Importantly, we found that cholesterol 
and mevalonate treatment can enhance cell motility, highlighting that the two metabolites are related 
to breast cancer aggressiveness. 
Metabolic reprogramming is a hallmark of cancer; altered metabolic pathways are indeed 
prognostic markers of disease and very important pharmacological targets for cancer therapy [58,59]. 
Depending on the availability of nutrients, some cells within the tumor are predominantly glycolytic, 
while others have a phenotype dependent on oxidative phosphorylation [60,61]. Therefore, we 
evaluated the energy profile of cells treated with mevalonate or cholesterol and the results indicate 
the ability of these metabolites to increase the two main cellular energy pathways: Glycolysis and 
oxidative phosphorylation. These results were confirmed by cytofluorimetric analysis performed in 
order to evaluate the mitochondrial mass, mitochondrial potential, and their ratio, known as the 
index of mitochondrial function. Our findings showed that the mitochondrial membrane potential 
increased in all tested breast cancer cells, while the mitochondrial mass only increased in triple 
negative cell lines. Importantly, the ratio of mitochondrial membrane potential versus mitochondrial 
mass increased in all breast cancer cells examined. We demonstrated that this is completely related 
to the effect of cholesterol and mevalonate on ERRα and the signaling pathways that it triggers. In 
particular, PGC-1α and ERbB2/HER2, involved in mitochondria biogenesis and the stimulation of 
oxidative metabolism, respectively, were affected. In this context, we proved that the effect of the two 
metabolites was reverted in MCF-7 cells treated with mevalonate or cholesterol in the presence of 
XCT790—the ERRα inhibitor. 
In addition to that, we showed that mevalonate and cholesterol increase the growth and 
propagation of CSCs, representing the subpopulation of tumor cells mainly responsible for cancer 
resistance, recurrence, and metastasis. CSCs have a high metabolic flexibility that allows them to 
switch between the glycolytic and phosphorylative pathways, according to the energy needs of the 
malignant cell [62–64]. Indeed, our results indicate that mevalonate and cholesterol promote CSC 
formation and propagation, increasing their energy metabolism and promoting the metabolic 
flexibility responsible for their aggressiveness. 
In order to better define the contribution of mevalonate and cholesterol in resistance to anti-
cancer therapy used in clinical practice, we focused our attention on lipid droplets (LDs), which have 
increasingly become a major topic of research during last years. Recent studies have explained that 
LDs are not passive cytoplasmic structures, but interact with different organelles to modulate several 
cellular processes [65]. Increased LD formation in cancer cells can be correlated with anti-cancer 
therapy resistance. Resistance to anti-cancer drugs is a persistent problem in treating tumors and 
varies tremendously among different cancer types, but lipid metabolism can be a common crucial 
contributor [66,67]. Interestingly, we demonstrated that the activation of ERRα, by cholesterol or 
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mevalonate treatment, noticeably increased the perilipin expression level. Our results are in 
agreement with the high levels of TPD52 protein detected in MCF-7 cells after mevalonate or 
cholesterol treatment. Both proteins are related to lipid droplet formation [68]. Indeed, our findings 
established that treatment with cholesterol or mevalonate is able to increase the amount of perilipin-
2 in all breast cancer cell lines examined, determining a further feature that could lead to greater 
aggressiveness and resistance to pharmacological treatments currently used in clinical practice, 
induced by mevalonate and cholesterol treatment. 
These data, altogether, suggest that cholesterol or mevalonate treatment, through the activation 
of ERRα and related pathways, can significantly reduce the antiproliferative and cytotoxic effects of 
clinically used tamoxifen and doxorubicin. These metabolic and biological changes, induced by the 
treatments, are used by the breast cancer cell to develop a resistant and aggressive phenotype. 
Overall, our outcomes highlight how high cholesterol levels are able to trigger, by themselves, 
aggressiveness and tumor resistance. Moreover, the results obtained in this study showed very 
similar effects induced by the treatment with mevalonate, which can be traced back to its conversion 
to cholesterol. Furthermore, Kaplan–Meier analyses, performed on patients with any breast cancer 
subtype, confirmed that a poor prognosis is associated with high levels of ERRα [69,70], opening new 
scenarios in the treatment of breast cancer in light of the strong connection between 
mevalonate/cholesterol and activation of the ERRa pathway. 
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